Patents by Inventor Nadia Anceriz

Nadia Anceriz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR NEOADJUVANT TREATMENT IN CANCER
    Publication number: 20260191954
    Abstract: The present invention relates to antibodies that inhibit the enzymatic activity of human CD39 and methods of using the compounds to treat cancer, including in combination with an anti-PD(L)1 antibody. The anti-CD39 antibody and the anti-PD(L)1 antibody can be administered as neoadjuvant therapy to treat lung cancer. The invention also relates to dosing regimens for combination treatment with anti-CD39 antibody and an anti-PD(L)1 antibody.
    Type: Application
    Filed: November 30, 2023
    Publication date: July 9, 2026
    Inventors: NADIA ANCERIZ, CHUNLING FAN, ZACHARY COOPER, CAROLINE DENIS, JAMES EDWARD EYLES, PAULA FRAENKEL, CARINE PATUREL, ERIC TU
  • NKp46 binding agents
    Patent number: 12365731
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Grant
    Filed: June 29, 2022
    Date of Patent: July 22, 2025
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
  • MULTISPECIFIC NK ENGAGER PROTEIN
    Publication number: 20250215107
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: January 6, 2025
    Publication date: July 3, 2025
    Inventors: Laurent GAUTHIER, Nadia ANCERIZ, Ariane MOREL, Benjamin ROSSI
  • Multispecific NK engager protein
    Patent number: 12252543
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: March 18, 2025
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • VARIABLE REGIONS FOR NKP46 BINDING PROTEINS
    Publication number: 20240174748
    Abstract: The application pertains to NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: February 5, 2024
    Publication date: May 30, 2024
    Inventors: LAURENT GAUTHIER, NADIA ANCERIZ, ARIANE MOREL, BENJAMIN ROSSI
  • MULTISPECIFIC NKp46 BINDING PROTEINS
    Publication number: 20240141042
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infections disease.
    Type: Application
    Filed: October 20, 2023
    Publication date: May 2, 2024
    Inventors: Laurent GAUTHIER, Nadia ANCERIZ, Ariane MOREL, Benjamin ROSSI
  • Variable regions for NKp46 binding proteins
    Patent number: 11891444
    Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: February 6, 2024
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • NKp46 binding proteins
    Patent number: 11845795
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 19, 2023
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • NKp46 BINDING AGENTS
    Publication number: 20220340661
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Application
    Filed: June 29, 2022
    Publication date: October 27, 2022
    Inventors: NADIA ANCERIZ, MATHIEU BLERY, LAURENT GAUTHIER, CARINE PATUREL
  • NKp46 binding agents
    Patent number: 11377492
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: July 5, 2022
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Mathieu Blery, Laurent Gauthier, Carine Paturel
  • Multispecific NK engager protein
    Patent number: 11267897
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: March 8, 2022
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • VARIABLE REGIONS FOR NKP46 BINDING PROTEINS
    Publication number: 20210269523
    Abstract: NKp46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: May 10, 2021
    Publication date: September 2, 2021
    Inventors: LAURENT GAUTHIER, NADIA ANCERIZ, ARIANE MOREL, BENJAMIN ROSSI
  • Variable regions for NKp46 binding proteins
    Patent number: 11001629
    Abstract: NKp-46-binding immunoglobulin variable regions, and proteins such as antibodies and multispecific proteins that comprise the variable regions are provided. The proteins can bind and specifically redirect NK cells to lyse a target cell of interest. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: May 11, 2021
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • Methods for detecting tissue infiltrating NK cells
    Patent number: 10736963
    Abstract: The present invention relates to methods for detecting and monitoring NK cells in paraffin-embedded tissue samples. Also provided are antibodies, antibody fragments, and derivatives thereof that specifically bind to NKp46 present on the surface of NK cells in paraffin-embedded tissue samples.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: August 11, 2020
    Assignee: INNATE PHARMA
    Inventors: Nadia Anceriz, Cecile Bonnafous, Arnaud Dujardin, Carine Paturel
  • NKp46 BINDING PROTEINS
    Publication number: 20200131268
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: November 8, 2019
    Publication date: April 30, 2020
    Inventors: Laurent GAUTHIER, Nadia ANCERIZ, Ariane MOREL, Benjamin ROSSI
  • NKp46 binding proteins
    Patent number: 10519234
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: December 31, 2019
    Assignee: INNATE PHARMA
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • NKp46 BINDING AGENTS
    Publication number: 20190367609
    Abstract: The present invention provides antigen-binding proteins capable of binding to NKp46 polypeptides. The antigen-binding proteins have increased activity in the treatment of disorders characterized by NKp46-expressing cells, particularly tumor cells.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 5, 2019
    Inventors: NADIA ANCERIZ, MATHIEU BLERY, LAURENT GAUTHIER, CARINE PATUREL
  • MULTISPECIFIC NK ENGAGER PROTEIN
    Publication number: 20190055315
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 21, 2019
    Inventors: Laurent Gauthier, Nadia Anceriz, Ariane Morel, Benjamin Rossi
  • MULTISPECIFIC NK ENGAGER PROTEIN
    Publication number: 20190048093
    Abstract: Multispecific proteins that bind and specifically redirect NK cells to lyse a target cell of interest are provided without non-specific activation of NK cells in absence of target cells. The proteins have utility in the treatment of disease, notably cancer or infectious disease.
    Type: Application
    Filed: October 29, 2018
    Publication date: February 14, 2019
    Inventors: Laurent GAUTHIER, Nadia ANCERIZ, Ariane MOREL, Benjamin ROSSI
  • METHODS FOR DETECTING TISSUE INFILTRATING NK CELLS
    Publication number: 20180369373
    Abstract: The present invention relates to methods for detecting and monitoring NK cells in paraffin-embedded tissue samples. Also provided are antibodies, antibody fragments, and derivatives thereof that specifically bind to NKp46 present on the surface of NK cells in paraffin-embedded tissue samples.
    Type: Application
    Filed: July 4, 2016
    Publication date: December 27, 2018
    Inventors: NADIA ANCERIZ, CECILE BONNAFOUS, ARNAUD DUJARDIN, CARINE PATUREL